Patients with Hematological Malignancies Treated with T-Cell or B-Cell Immunotherapy Remain at High Risk of Severe Forms of COVID-19 in the Omicron Era

Background: Patients with hematological malignancies are at greater risk of severe COVID-19 and have been prioritized for COVID-19 vaccination. A significant proportion of them have an impaired vaccine response, both due to the underlying disease and to the treatments. Methods: We conducted a prospe...

Descripción completa

Detalles Bibliográficos
Autores principales: Zerbit, Jeremie, Detroit, Marion, Meyer, Antoine, Decroocq, Justine, Deau-Fischer, Benedicte, Deschamps, Paul, Birsen, Rudy, Mondesir, Johanna, Franchi, Patricia, Miekoutima, Elsa, Guerin, Corinne, Batista, Rui, Bouscary, Didier, Willems, Lise, Vignon, Marguerite
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9696091/
https://www.ncbi.nlm.nih.gov/pubmed/36366475
http://dx.doi.org/10.3390/v14112377

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9696091/
https://www.ncbi.nlm.nih.gov/pubmed/36366475
http://dx.doi.org/10.3390/v14112377

Ejemplares similares